Solid tumour cellular therapy - principles of toxicity management.

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Recent FDA approvals of lifileucel and afami-cel for advanced melanoma and synovial sarcoma highlight the growing use of adoptive cellular therapies (ACTs) in solid tumors.
• The increasing implementation of these advanced therapy medicinal products necessitates a comprehensive understanding of their associated toxicities.
• First-generation tumor-infiltrating lymphocyte (TIL) therapies present unique toxicities distinct from gene-modified T-cell therapies like CAR T and TCR T, posing new challenges for clinicians.

Purpose of the Study:

• To provide guidance on managing toxicities associated with ACTs for solid tumors.
• To discuss the core principles for toxicity management in the context of emerging ACTs.
• To prepare healthcare professionals for the increasing use of ACTs in solid tumor treatment.

Main Methods:

• Extrapolation of experience from chimeric antigen receptor T-cell (CAR T) therapy in hematologic malignancies.
• Review of historical use of high-dose interleukin-2 in solid tumor regimens.
• Analysis of recent data from lifileucel and afami-cel approvals and management.

Main Results:

• Development of core principles for managing ACT-related toxicities in solid tumors.
• Identification of unique toxicity profiles for TIL therapies compared to other ACTs.
• Establishment of a foundation for healthcare professionals managing these novel treatments.

Conclusions:

• Effective toxicity management is crucial for the successful implementation of ACTs in solid tumors.
• A foundational knowledge of toxicity management principles is essential for healthcare professionals in this rapidly evolving field.
• Continued development and understanding of ACTs will improve patient outcomes in solid tumor treatment.